chief

fitness

Onnit’s Chief Fitness Officer Discovered His ‘Non-Negotiables’ in 2020

This article originally appeared in the December 2020 issue of Men’s Health.



Onnit Chief Fitness Officer John Wolf shares some of the most important lessons he's learned while adjusting to the challenges that arose in 2020.


© Kyle Hilton
Onnit Chief Fitness Officer John Wolf shares some of the most important lessons he’s learned while adjusting to the challenges that arose in 2020.

JOHN WOLF’S job is all about thinking in new ways to break away from conventions—but 2020 was still an unprecedented challenge for him.

The man tasked with leading the fitness curriculum at Onnit, the company behind some of the most unconventional, versatile workout gear on the market, had to adjust the ways he approaches both his work and family.

He wound up building stronger connections than ever before.

Now, in his own words, Wolf shares the lessons he’s learned through a period that was challenging and isolating—but which ultimately led to deeper connections and a renewed sense of focus.



background pattern: breaker


© .
breaker

I think fitness is taking on a little more of a mental-emotional aspect during this pandemic. It is a thing that people have doubled down on in a variety of different ways, but it looks and feels so much different than it did before.

The availability of the equipment is a big issue these days. It’s forced kind of a Spartan and minimalist mindset, like, ‘How creative do I have to be to get the job done?’

Some of the coaching I’ve gone through for personal improvement is what I lean on in this larger group environment because it’s not like everybody looks the same. Not everybody has the same interests—except for everybody feels that they’re alone, to some degree, that their circumstances are uniquely theirs … Then through breaking down the barriers in the group, and me also being vulnerable to my experiences live and being forthright with them about those things, hoping that we’re facilitating an environment where people realize okay, the circumstances might all be really different, but the subjective experience that we’re all having is very consistent as human beings.



logo: Click here to join for more exclusive health and fitness stories.


© .
Click here to join for more exclusive health and fitness stories.

In this day and age, right now, the sense of feeling seen and feeling heard—to feel validated on some platform in some way—takes on a greater meaning and grander meaning than it ever has before… That’s really the biggest message, you show up here and you are seen and you are heard, and that even just that the act of showing up is enough to participate.

If it’s a nice day, we create a space where we can go for an hour-long walk as a pack. Walking together creates either quiet time, being around each other, being okay being quiet, and/or the perfect storm, the perfect opportunity to be able to converse about things that matter and observe the world around us at a tempo where there’s actually time to see something. You drive down the same street, you don’t see the detail on that flower. You might not even notice that those flowers bloomed between yesterday and today.

If you’re

Read More
medicine

United Family Medicine Board Names Chief Executive Officer

ST. PAUL, Minn.–(BUSINESS WIRE)–United Family Medicine (UFM), a federally-qualified health center (FQHC) in St. Paul dedicated to meeting the health care demands of its community while contributing to the vitality of the region, announced today that its board of directors promoted Ann Nyakundi to CEO effective immediately.

Nyakundi joined the organization as interim CEO in October 2019, establishing priorities to re-design UFM’s care model to improve patients’ access to its services, maintain highest level health outcomes, and achieve compliance with the Health Resources Services Administration (HRSA), its federal regulator and primary funder. The resulting transformative changes, including migrating from its Allina-leased provider arrangement to hiring its own full complement of physicians, place UFM on track to attain regulatory compliance, while improving patients’ ability to see their doctors and health care team more quickly than ever before.

“It’s my desire and our collective responsibility to provide the best health care possible to every one of our patients, at the time that they need it, and we’re making numerous changes to meet this commitment,” said Nyakundi. “I’m grateful to UFM’s board of directors for the confidence it’s placed in me as its CEO, and excited to continue our work to place patients at the center of our response to community needs.”

Through the onset and continuing stressors of the Covid-19 pandemic, Nyakundi empowered her teams to improve access to care, such as the advanced practitioners who launched telemedicine as a service. This prompt response resulted in UFM regaining most of the patient visits that were delayed due to the pandemic, while significantly reducing UFM’s operating deficit and reliance on a part-time physician workforce. These cost efficiencies will allow UFM to expand dental and other services.

“Ann’s skill as a health care leader and her ethical and motivational orientation has steered United Family Medicine forward through the extreme challenges that its operating structure posed and the Covid-19 pandemic continues to present,” said Daymond Dean, UFM Executive Committee Board Member. “Our patients’ lives and well-being depend on their ability to receive the services that a community health center provides, and Ann is immeasurably qualified to ensure that UFM delivers those services and high-quality health care to our community.

Nyakundi pursued undergraduate and graduate medical anthropology and health care administration at the University of Michigan and University of Minnesota respectively, and brings to her role expertise in community health, philanthropy, strategic planning and health policy. Having experienced homelessness as a child without access to adequate options for high quality health care, inspired her career and commitment to public health. Most recently she volunteered for the Agency for Healthcare Research and Quality (AHRQ) as a National Expert for the New Models of Primary Care Workforce and Financing Project, provided strategic support to the National Marrow Donor Program and worked within the Primary Care Services Division of the American Cancer Society.

About United Family Medicine

United Family Medicine, a federally qualified health center in St. Paul, Minnesota, provides high quality primary care, dental services and

Read More
medicine

PM Modi thanks WHO chief for choosing India for global centre of traditional medicine



Narendra Modi looking at the camera: PM Modi thanks WHO chief for choosing India for global centre of traditional medicine


© Saurav Mukherjee
PM Modi thanks WHO chief for choosing India for global centre of traditional medicine

The World Health Organization (WHO) will set up a Global Centre for Traditional Medicine in India to strengthen the evidence, research, training and awareness of traditional and complementary medicine. WHO Director-General Tedros Adhanom Ghebreyesus made the announcement at an event on November 13 in which Prime Minister Narendra Modi inaugurated two future-ready Ayurveda institutions in Jaipur and Jamnagar via video conferencing on the occasion of the 5th Ayurveda Day.

In a video message, Ghebreyesus said, “I am pleased to announce that we have agreed to open a WHO Global Centre for Traditional Medicine in India to strengthen the evidence, research, training and awareness of traditional and complementary medicine.”

“This new centre will support WHO’s efforts to implement its traditional medicine strategy 2014-2023 which aims to support countries in developing policies and action plans to strengthen the role of traditional medicine as part of their journey to universal health coverage and a healthier, fairer and safer world,” he said.

Ghebreyesus praised PM Modi’s commitment to the universal coverage under Ayushman Bharat and evidence-based promotion of traditional medicines to achieve health-related objectives, the Prime Minister’s Office said in a statement.

The Prime Minister thanked WHO and its Director-General for choosing India as the Global Centre of Traditional medicine.

I am thankful Director General of @WHO, @DrTedros for choosing #India for Global Centre of Traditional medicine: PM @narendramodi #NationalAyurvedaDay https://t.co/a9vyzOYdXD pic.twitter.com/YwyVYq9SaL

— PIB India (@PIB_India) November 13, 2020

“It is a matter of pride for all Indians that the WHO has chosen India for establishing its Global Centre for Traditional Medicine. Now work will be done in this direction from India,” Modi said.

“I would like to thank the WHO and particularly its Director General Tedros for giving this responsibility to India. I am confident that just like India has emerged as the pharmacy of the world, in the same manner this centre for traditional medicine will become the centre for global wellness,” he said.

(With inputs from PTI)

Source Article

Read More
medicine

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D. In connection with Dr. Michaels’ appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Dr. Michaels as inducements material to Dr. Michaels entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of $30.41 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Michaels’ employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Michaels’ continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Dr. Michaels’ employment start date until the fourth anniversary of Dr. Michaels’ employment start date, subject to Dr. Michaels’ continued service to Editas Medicine through the applicable vesting dates.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

CONTACT: Contacts: Media Cristi Barnett (617) 401-0113 [email protected] Investors Mark Mullikin (617) 401-9083 [email protected]

Source Article

Read More
medicine

Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company’s Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michaels will lead clinical research and drug development for the Company’s pipeline of experimental medicines.

“We are thrilled to have Lisa join our team, bringing her ability to translate concepts from ‘bench to bedside’, with proven results in design and execution of multinational clinical trials,” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine. “Her corporate and academic drug development expertise will be instrumental in advancing our mission to develop and deliver transformative medicines to people living with serious diseases.”

Lisa Michaels, M.D., Executive Vice President and Chief Medical Officer, Editas Medicine, commented, “Editas Medicine is a leader in the development of the next generation of medicines to treat diseases with few approved medicines. I am excited to join the team as we just reacquired the rights to our ocular pipeline and are on the cusp of bringing EDIT-301, our potentially best-in-class medicine for the treatment of sickle cell disease, to the clinic. I look forward to working with the team to advance the development of EDIT-101, EDIT-301, and EDIT-201 in the near term as well as additional medicines in the future to treat serious diseases with unmet medical needs.”

Dr. Michaels has more than 25 years of experience in clinical research and drug development in both industry and academia. Dr. Michaels joins Editas Medicine from Bayer Pharmaceuticals where she spent more than 10 years in drug development, leading teams from early research and drug discovery through regulatory approval, commercial launch, and life cycle management. Most recently, she served as head of Bayer’s Rare Diseases, Cell & Gene Therapy therapeutic area.

Earlier in her career, Dr. Michaels spent more than 15 years at the Robert Wood Johnson Medical School at Rutgers University in academic practice, working in areas including benign and malignant hematology, solid tumors, bone marrow failure syndromes, thrombosis and hemostasis, and immunologic disorders including cytopenias and immune deficiencies.

Dr. Michaels received her M.D. at the University of Virginia, Charlottesville during which she received additional training in translational research in autoimmune disease, immune deficiencies, and disorders of complement, at the National Institute for Allergy and Infectious Disease in Washington, DC, and completed a preceptorship in pediatric cardiovascular care at Mayo Clinic, in Rochester, Minnesota. Dr. Michaels completed her residency and qualification in pediatrics at Duke University and post-graduate fellowship and qualification in hematology and oncology at the Children’s Hospital of Philadelphia.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of

Read More
fitness

Syracuse police chief to serve in ‘civilian capacity’ because he can’t pass state fitness test

Syracuse, N.Y. — Syracuse Police Chief Kenton Buckner said Friday that he will serve in a “civilian capacity” atop the police department because he cannot pass a stringent physical fitness test required of sworn officers.

Buckner, who became chief in December 2018, said he is unable to run 1.5 miles in about 13 minutes.

“While I have improved my fitness and can complete the majority of the physical requirements, I am unable to finish the 1.5 mile run in the required time,” Buckner said in a statement. “With the next deadline approaching early December, I have decided at this time not to continue to pursue state certification.”

The lack of state certification does not impact the chief’s ability to serve, Buckner said in the statement.

But “out of respect for the certification process and all those who have completed it,” Buckner will not wear a police uniform while serving as chief.

Buckner, who was hired from his previous position as chief of police in Little Rock, Ark., came here on a provisional basis until he was able to get certified as a New York officer. In the meantime, he’s been afforded all the rights of a standard cop, including carrying a gun and badge.

The state’s Department of Criminal Justice Services allows one year for an out-of-state transfer to get certified here. That certification, for Buckner, included 386 hours of training as well as a physical fitness exam.

In November 2019, he was given a one-year extension to pass the certification requirements, but he announced Friday he would no longer seek the certification.

Buckner will no longer have arrest powers or be allowed to carry a gun, but he stressed that he will carry out all his administrative duties in charge of the department as before.

“I had my own private disappointment moments, but I thought it was important enough given my position in the city to be transparent,” he said of the decision not to seek the certification and why he announced it Friday. “… Everyone knows how tough it is to get in shape.”

Mayor Ben Walsh, at a news conference, praised Buckner’s performance as chief and said the lack of certification should not make the public doubt his ability to run the department.

“His ability or lack thereof to run a mile and a half in under 13 minutes has absolutely no bearing on his ability to do the job,” Walsh said.

The Syracuse police union has made an issue of Buckner’s certification. The union clashed with Buckner in early 2019 over public comments the chief made about officer behavior, among other things. Many officers refused to march in the annual St. Patrick’s Parade in a public display of discord with the chief.

Buckner’s full statement is below:

Today, Syracuse Police Chief Kenton Buckner announced he would not continue to pursue New York State police officer certification. Under local and state law, the Chief is not required to be a sworn officer. Chief Buckner is able to

Read More
health

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005064/en/

Dr Suhail Nurbhai. High-resolution images available on request. (Photo: Business Wire)

Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. He joins Mission from VHsquared, where he held the position of CMO since 2014.

Prior to VHsquared, Suhail was Senior Vice President and Head of Development and Medical Affairs for Shionogi in Europe. He joined Shionogi from Takeda where he was Vice President and Head of Clinical and Analytical Science in Europe, with responsibility for all Clinical Science activities in Neurosciences, Cardiovascular/Renal/Metabolic, Oncology, Gastrointestinal/Genitourinary and Respiratory Medicine, as well as Clinical Pharmacology, Medical Writing, Statistics and Data Management.

Suhail’s initial industry experience was at Pfizer, where he spent 12 years, initially in Sandwich, UK and then at Global R&D Headquarters in Connecticut, USA. During his time at Pfizer he held roles of increasing responsibility across multiple therapeutic areas including GI/GU, anti-bacterial, sexual medicine and anti-fungal, prior to completing his time at Pfizer as Head of Neuroscience Clinical R&D at the Groton site in Connecticut.

During his career he has led teams bringing multiple compounds from pre-clinical phase into clinical studies in both Europe and US, and achieved multiple successful NDA and MAA submissions and approvals.

Suhail qualified in Medicine at Dundee University in Scotland and completed his post-graduate medical training at Hope Hospital in the University of Manchester.

Commenting on the appointment, Dr Anker Lundemose, CEO of Mission Therapeutics said: “We are pleased to be welcoming Suhail to further strengthen Mission’s leadership team. His in-depth knowledge and proven track record in clinical research will be invaluable as we work to bring our first-in-class USP30 inhibitor compound into the clinic. Suhail’s appointment is the last of a series of organisational changes, including the promotions of Dr Paul Thompson and Dr Nick Edmunds, to ready the Company for this next phase.”

Dr Suhail Nurbhai added: “It’s great to be joining Mission at such an exciting time for the Company. The ongoing collaboration with AbbVie and recently signed agreement with Pfizer represent solid industry validation of the Company’s approach and ground-breaking technology. I look forward to building on this success progressing its lead assets into the clinic.”

– ENDS –

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong

Read More
health

WHO chief self-quarantining after contact with person who tested positive for coronavirus

The World Health Organization Director-General Tedros Adhanom Ghebreyesus announced late Sunday he was self-quarantining after coming into contact with someone who tested positive for the novel coronavirus.

“I have been identified as a contact of someone who has tested positive for #COVID19,” Tedros wrote on Twitter. “I am well and without symptoms but will self-quarantine over the coming days, in line with @WHO protocols, and work from home.”

The announcement comes as the coronavirus has totaled at least 46,426,677 worldwide cases and more than 1,199,684 deaths, as of Sunday night, according to data from Johns Hopkins University. 

4 CORONAVIRUS TREATMENTS, INCLUDING REMDESIVIR, HYDROXYCHLOROQUINE, FLOP IN LARGE WHO STUDY

Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), addresses a press conference about the update on COVID-19 at the World Health Organization headquarters in Geneva, Switzerland on Feb. 24, 2020. (Salvatore Di Nolfi/Keystone via AP, File)

Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), addresses a press conference about the update on COVID-19 at the World Health Organization headquarters in Geneva, Switzerland on Feb. 24, 2020. (Salvatore Di Nolfi/Keystone via AP, File)

Tedros is currently in Geneva, which is home to WHO headquarters, according to his Twitter bio. On Sunday, the city announced a partial lockdown, following an outbreak of cases and hospitalizations due to the virus.

“On November 1, 474 people are being treated by the University Hospitals of Geneva (HUG), including 56 in intensive care beds (intensive and intermediate care). As a reminder, in mid-October, the HUG had 78 hospitalizations, including 13 in intensive care beds,” a statement by the cantonal government said.

“The figures show that the situation is severely worsening. Over the past few days, more than 1,000 people have tested positive for coronavirus on a daily basis,” the statement continued.

According to WHO guidelines cited by Tedros, the agency “recommends that all contacts of individuals with a confirmed or probable COVID-19 be quarantined in a designated facility or at home for 14 days from their last exposure.”

HEALTHY YOUNG PEOPLE MAY WAIT FOR CORONAVIRUS VACCINE UNTIL 2022, WHO OFFICIAL SAYS

On Sunday, he wrote that it was “critically important that we all comply with health guidance.”

CLICK HERE FOR THE FOX NEWS APP

“This is how we will break chains of #COVID19 transmission, suppress the virus, and protect health systems,” Tedros added. “My @WHO colleagues and I will continue to engage with partners in solidarity to save lives and protect the vulnerable. Together!”

Source Article

Read More
health

N.J.’s medical marijuana chief douses senator’s pipe dream of legal weed for sale immediately after the election

EDITOR’S NOTE: NJ Cannabis Insider produces exclusive weekly content and monthly events geared toward those interested in the marijuana and hemp industries. To subscribe, visit njcannabisinsider.biz.

Not long after state Sen. Nick Scutari claimed on Tuesday legislators and regulators may “be able to flip the switch and people might be able to get marijuana, legally, right after the vote,” the head of the state medical cannabis program doused that pipe dream with a bucket of cold water.

“(Some dispensaries) literally do not even have the space to accommodate the level of demand that personal-use sales would bring,” said Jeff Brown, who helms the Department of Health’s Medicinal Marijuana Program. “I could say unequivocally that opening up sales even a few months after the election would be a disaster and would really hurt access for patients who need this as medicine. My number one priority is to ensure that the patients have access — that’s going to be our priority first and foremost.”

Since the passage of Jake Honig’s Law, the medical program continues to grow in terms of patients and demand — about 7,000 patients per month on average and nearly 95,000 patients enrolled in total — but the program continues to face supply challenges for just the current patient population due to the small number of operational cultivators and canopy space.

Scutari, in his comments during an interview with NJ Cannabis Insider streamed live on NJ.com’s Facebook page Tuesday, that “(the) currently operating medical cannabis dispensaries would have an opportunity to sell to the general public for people over 21, if they can certify that they have enough product to satisfy their patients that they’re already treating.”

Brown, who also participated in a closed portion of the webinar, tamped down the senator’s suggestion at the time. He said he wants to keep an open dialogue with legislators and make the program’s priorities clear to medical patients and Garden State citizens as a whole.

“Inventories at alternative treatment centers are increasing, too, but it’s uneven,” he said. “We have some that are expanding capacity and then we have others that are simply maintaining and have really no room to expand cultivation in their current footprints.”

For the past six months, Brown said, the medical cannabis program has averaged about only 2,100 pounds in sales per month, rising to nearly 2,500 in September with a similar trend in October. Based on an average of the patient population, patients typically only buy a half-ounce each month, he said.

As of this past Friday, Brown said, there were about 10,000 pounds of medical cannabis in the market — about evenly split between flower and extracts, though flower tends to have higher sales. That means there’s enough medical cannabis to last about four months, given current sales trends and more limited choices for patients.

Part of the challenges dispensaries face, Brown said, is the small indoor canopy. There’s a dozen cultivators in New Jersey, but the average dispensary only has a canopy of

Read More
health

Space Force vice chief of space operations tests positive for COVID-19

Lt. Gen. David D. Thompson, Vice Commander of the United States Space Force, seen at the Air Force Association, Air Warfare Symposium in Orlando, Fla., in February, tested positive for COVID-19 this week. Photo by Jonathan Snyder/U.S. Air Force

Lt. Gen. David D. Thompson, Vice Commander of the United States Space Force, seen at the Air Force Association, Air Warfare Symposium in Orlando, Fla., in February, tested positive for COVID-19 this week. Photo by Jonathan Snyder/U.S. Air Force

Oct. 29 (UPI) — Space Force’s vice chief of space operations tested positive for COVID-19 Wednesday, Space Force announced.

According to a press release issued jointly by the Space Force and the Air Force, Gen. David D. Thompson took a test for the virus after learning that a close family member had tested positive.

Air Force spokeswoman Ann Stefanek said Thompson has not shown symptoms of COVID-19 so far and was on leave last week, but returned to the Pentagon for work on Monday and Tuesday to address a virtual symposium for the National Defense Industrial Association and Texas A&M University.

He is now self-isolating and working from home.

According to Stefanek, Chief of Space Operations Gen. John W. “Jay” Raymond, Air Force Chief of Staff Gen. Charles Q. Brown, Jr., and Air Force Secretary Barbara M. Barrett have not tested positive for the new virus within the past 24 hours.

Raymond and Brown recently ended a period of isolation after a potential exposure among the Joint Chiefs of Staff.

“The Department of the Air Force continues to follow established DoD and Centers for Disease Control and Prevention policies and guidelines for COVID. Measures include temperature testing, social distancing to the greatest extent possible, the wearing of masks when social distancing is not possible, and contact tracing and quarantining, if needed,” the press release said.

As of Thursday morning a total of 55,443 COVID-19 cases had been reported in the military since the beginning of the pandemic, with 8,839 of those reported among Air Force personnel.

Earlier this month Marine Corps assistant commandant Gen. Gary Thomas and Adm. Charles Ray, vice commandant of the U.S. Coast Guard, tested positive for COVID-19.

And last week United States Forces Korea said 13 service members had tested positive for the virus, the second time in two weeks that USFK reported personnel arriving in Korea had tested positive.

Source Article

Read More